YOLFTbeta
BioInfra Co., Ltd.

BioInfra Co., Ltd.

199730 · KQ · Healthcare / Biotechnology

1,430.00KRW-192.00 (-11.84%)

Price History

Full chart

Market Stats

Previous Close1,622.00
Open1,603.00
Day Range1,411.00 – 1,649.00
52-Week Range593.00 – 5,390.00
Volume429.96K
Market Cap2.93B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield44.25%
Beta0.41
50-Day Avg1,435.06
200-Day Avg3,261.12

About

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances. The company was founded in 2007 and is based in Yongin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sangdeuk Lee
  • Headquarters120 Heungdeokjungang-ro, Yongin-si, South Korea, Korea
  • Websitehttps://www.bioinfrakorea.co.kr

Leadership

  • Mr. Sangdeuk LeeCEO & Inside Director · b. 1959
  • YoungGuk LeeExecutive Inside Director

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue35.43B30.13B23.83B23.15B
Growth (%)--14.96%-20.90%-2.87%
Cost of Revenue21.46B20.58B18.14B17.82B
Gross Profit13.97B9.55B5.70B5.32B
Gross Margin39.44%31.71%23.90%23.00%
Operating Expense7.61B8.25B10.81B11.59B
Operating Income6.36B1.31B-5.12B-6.27B
Operating Margin17.95%4.33%-21.47%-27.08%
EBITDA9.34B4.09B-2.18B-4.32B
EBITDA Margin26.35%13.59%-9.16%-18.67%
Net Income6.24B2.00B-3.98B-9.13B
Net Income Margin17.61%6.64%-16.68%-39.45%
R&D4.01B4.49B6.96B8.01B
R&D as % of Total Revenue11.31%14.90%29.20%34.60%
Interest Expense369.51M427.30M376.56M367.18M
Interest Expense % of Total Revenue1.04%1.42%1.58%1.59%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets32.59B47.00B41.12B34.96B
Total Liabilities14.68B13.03B13.55B18.47B
Total Equity17.91B33.97B27.57B16.49B
Cash7.36B10.69B4.03B2.14B
Net Debt913.98M-4.17B8.56B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow8.42B679.30M1.73B-1.50B
Capital Expenditure10.68B3.70B2.87B1.53B
Free Cash Flow-2.26B-3.02B-1.14B-3.03B
Dividends Paid--2.88B1.95B
FCF to OCF-26.79%-444.35%-66.03%201.65%
Dividend Paid to FCF---252.07%-64.27%

Earnings

Report DateMar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------
EPS Actual-138.54151.5787.80316.46-307.85-253.00-243.39-16.92-357.62-328.53-454.00-736.97-512.990.31
Surprise--------------
Timing--------------

Key Statistics & Ratios

Market Cap2.93B
Enterprise Value10.47B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.11
Price / Book0.30
Revenue (TTM)25.62B
Gross Profit (TTM)6.45B
EBITDA-1.74B
Profit Margin-32.34%
Operating Margin0.89%
Return on Equity-47.52%
Return on Assets-9.12%
Shares Outstanding4.86M
Shares Float2.36M
Beta0.41
Dividend Yield44.25%
Dividend Rate300.00
Payout Ratio223.05%

Dividends

20251×
300.00Dec 29, 2025
20241×
400.00Dec 27, 2024
20231×
600.00Dec 27, 2023